Evidence map›Paper›PMID 36225925›Full record

ArticleFrontiers in immunology2022

Humoral response and neutralising capacity at 6 months post-vaccination against COVID-19 among institutionalised older adults in Argentina.

Pamela E Rodriguez, Andrea P Silva, Esteban A Miglietta, Pablo Rall, Carla A Pascuale, Christian Ballejo, Lucía López Miranda, Antonella S Ríos, Lila Ramis, Jimena Marro and 12 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Pamela E RodriguezFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Andrea P SilvaDepartamento Laboratorio de Diagnóstico y Referencia, Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Mar del Plata, Argentina.
Esteban A MigliettaFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Pablo RallInstituto Nacional de Servicios Sociales para Jubilados y Pensionados (INSSJP-PAMI), Buenos Aires, Argentina.
Carla A PascualeFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Christian BallejoDepartamento de Investigación Epidemiológica, Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Mar del Plata, Argentina.
Lucía López MirandaDepartamento Laboratorio de Diagnóstico y Referencia, Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Mar del Plata, Argentina.
Antonella S RíosFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Lila RamisFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Jimena MarroDepartamento de Investigación Epidemiológica, Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Mar del Plata, Argentina.
Verónica PoncetDepartamento Laboratorio de Diagnóstico y Referencia, Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Mar del Plata, Argentina.
Bianca MazzitelliInstituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS)-CONICET, Facultad de Medicina Universidad de Buenos Aires (UBA), Buenos Aires, Argentina.
Melina SalvatoriInstituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS)-CONICET, Facultad de Medicina Universidad de Buenos Aires (UBA), Buenos Aires, Argentina.
Ana CeballosInstituto de Investigaciones Biomédicas en Retrovirus y Sida (INBIRS)-CONICET, Facultad de Medicina Universidad de Buenos Aires (UBA), Buenos Aires, Argentina.
María M Gonzalez Lopez LedesmaFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Diego S OjedaFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
María F AguirreDepartamento de Investigación Epidemiológica, Instituto Nacional de Epidemiología "Dr. Juan H. Jara", Mar del Plata, Argentina.
Yanina MiragayaInstituto Nacional de Servicios Sociales para Jubilados y Pensionados (INSSJP-PAMI), Buenos Aires, Argentina.
Andrea V GamarnikFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Andrés H RossiFundación Instituto Leloir-CONICET, Buenos Aires, Argentina.
Laboratorio SeVa Group
PAMI Group
Fundación Instituto Leloir · ARConsejo Nacional de Investigaciones Científicas y Técnicas · ARInstituto de Investigaciones Biomédicas en Retrovirus y Sida · ARUniversity of Buenos Aires · AR

Funding

Viral Immunity and VAccination (VIVA) Human Immunology Project Consortium (HIPC)U19AI168631 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Harm van Bakel · 2022 to 2026
$14.4M
NIAID NIH HHS U19 AI168631
6 · The paper itself

Abstract

The COVID-19 pandemic has particularly affected older adults residing in nursing homes, resulting in high rates of hospitalisation and death. Here, we evaluated the longitudinal humoral response and neutralising capacity in plasma samples of volunteers vaccinated with different platforms (Sputnik V, BBIBP-CorV, and AZD1222). A cohort of 851 participants, mean age 83 (60-103 years), from the province of Buenos Aires, Argentina were included. Sequential plasma samples were taken at different time points after vaccination. After completing the vaccination schedule, infection-naïve volunteers who received either Sputnik V or AZD1222 exhibited significantly higher specific anti-Spike IgG titers than those who received BBIBP-CorV. Strong correlation between anti-Spike IgG titers and neutralising activity levels was evidenced at all times studied (rho=0.7 a 0.9). Previous exposure to SARS-CoV-2 and age <80 years were both associated with higher specific antibody levels. No differences in neutralising capacity were observed for the infection-naïve participants in either gender or age group. Similar to anti-Spike IgG titers, neutralising capacity decreased 3 to 9-fold at 6 months after initial vaccination for all platforms. Neutralising capacity against Omicron was between 10-58 fold lower compared to ancestral B.1 for all vaccine platforms at 21 days post dose 2 and 180 days post dose 1. This work provides evidence about the humoral response and neutralising capacity elicited by vaccination of a vulnerable elderly population. This data could be useful for pandemic management in defining public health policies, highlighting the need to apply reinforcements after a complete vaccination schedule.

Indexed as

COVID-19AgedAged, 80 and overAntibodies, ViralArgentinaChAdOx1 nCoV-19HumansImmunoglobulin GPandemicsSARS-CoV-2VaccinationAntibodies, ViralChAdOx1 nCoV-19Immunoglobulin Gaging adultsanti-spike IgGAZD1222BBIBP-CorVneutralising antibodiesOmicronSARS-CoV-2Sputnik-V

Identifiers

PMID36225925
PMCPMC9549602
OpenAlexW4304687866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.